Terms: = Pancreatic cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
29 results:
1. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract] [Full Text] [Related]
2. Maximum Value on Arterial Phase Computed Tomography Predicts prognosis and Treatment Efficacy of Sunitinib for pancreatic Neuroendocrine Tumours.
Chen H; Li Z; Hu Y; Xu X; Ye Z; Lou X; Zhang W; Gao H; Qin Y; Zhang Y; Chen X; Chen J; Tang W; Yu X; Ji S
Ann Surg Oncol; 2023 May; 30(5):2988-2998. PubMed ID: 36310316
[TBL] [Abstract] [Full Text] [Related]
3. The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.
Muraishi N; Kawamura Y; Akuta N; Shindoh J; Matsumura M; Okubo S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Yasuda I; Kumada H
Oncology; 2023; 101(2):134-144. PubMed ID: 36103864
[TBL] [Abstract] [Full Text] [Related]
4. Identification of a DNA repair 9-gene signature for the overall survival prediction of pancreatic cancer.
Huang J; Mao Q; Sun X
Ann Diagn Pathol; 2022 Apr; 57():151883. PubMed ID: 35123152
[TBL] [Abstract] [Full Text] [Related]
5. CircCCT3 Acts as a Sponge of miR-613 to Promote Tumor Growth of pancreatic cancer Through Regulating VEGFA/vegfr2 Signaling.
Hou JP; Men XB; Yang LY; Han EK; Han CQ; Liu LB
Balkan Med J; 2021 Jul; 38(4):229-238. PubMed ID: 34274912
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating vegfr-2 signaling pathway in hepatocellular carcinoma.
Teng F; Zhang JX; Chang QM; Wu XB; Tang WG; Wang JF; Feng JF; Zhang ZP; Hu ZQ
J Exp Clin Cancer Res; 2020 Nov; 39(1):235. PubMed ID: 33168027
[TBL] [Abstract] [Full Text] [Related]
7. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for pancreatic cancer.
Fan Y; Li T; Xu L; Kuang T
Comput Math Methods Med; 2020; 2020():6138039. PubMed ID: 33062039
[TBL] [Abstract] [Full Text] [Related]
9. Relationship between SDC1 and cadherin signalling activation in cancer.
Liao S; Liu C; Zhu G; Wang K; Yang Y; Wang C
Pathol Res Pract; 2020 Jan; 216(1):152756. PubMed ID: 31810587
[TBL] [Abstract] [Full Text] [Related]
10. Fucoidan-Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Co-Targeting Tumor Hypoxia and Angiogenesis.
Shin SW; Jung W; Choi C; Kim SY; Son A; Kim H; Lee N; Park HC
Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30558324
[TBL] [Abstract] [Full Text] [Related]
11. Tumor and endothelial cells collaborate via transcellular receptor complexes.
Sarabipour S; Mac Gabhann F
J Pathol; 2019 Feb; 247(2):155-157. PubMed ID: 30357843
[TBL] [Abstract] [Full Text] [Related]
12. Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (vegfr) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Berardi R; Torniai M; Partelli S; Rubini C; Pagliaretta S; Savini A; Polenta V; Santoni M; Giampieri R; Onorati S; Barucca F; Murrone A; Bianchi F; Falconi M
PLoS One; 2018; 13(5):e0197035. PubMed ID: 29787601
[TBL] [Abstract] [Full Text] [Related]
13. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.
Han T; Luan Y; Xu Y; Yang X; Li J; Liu R; Li Q; Zheng Z
Cancer Biol Ther; 2017 Sep; 18(9):635-639. PubMed ID: 28678611
[TBL] [Abstract] [Full Text] [Related]
14. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract] [Full Text] [Related]
15. Emerging protein kinase inhibitors for treating pancreatic cancer.
Furuse J; Nagashima F
Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
[TBL] [Abstract] [Full Text] [Related]
16. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract] [Full Text] [Related]
18. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract] [Full Text] [Related]
19. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/vegfr2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract] [Full Text] [Related]
20. P53, hTERT, WT-1, and vegfr2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
Terashima T; Mizukoshi E; Arai K; Yamashita T; Yoshida M; Ota H; Onishi I; Kayahara M; Ohtsubo K; Kagaya T; Honda M; Kaneko S
Cancer Immunol Immunother; 2014 May; 63(5):479-89. PubMed ID: 24633336
[TBL] [Abstract] [Full Text] [Related]
[Next]
